AQST vs HALO
AQST: Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film platforms. HALO: Halozyme is a biopharmaceutical company that licenses its proprietary drug-delivery technology to help pharmaceutical partners convert intravenous treatments into more convenient subcutaneous injections.
Side-by-side fundamentals
| Metric | AQST | HALO | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $3.94 | $103.12 | |
| Market cap as of 2026-08-10 | $494M | $12.2B | |
| P/E as of 2026-08-10 | n/a | 29.57 | |
| PEG as of 2026-08-10 | -1.97 | 0.94 | AQST lower |
| Net margin as of 2026-08-10 | -137.1% | +24.9% | HALO higher |
| Gross margin as of 2026-08-10 | +63.5% | +82.4% | HALO higher |
| Operating margin as of 2026-08-10 | -111.2% | +35.6% | HALO higher |
| ROE as of 2026-08-10 | -21.8% | +180.6% | HALO higher |
| ROA as of 2026-08-10 | -49.3% | +16.6% | HALO higher |
| Debt / equity as of 2026-08-10 | 4.68 | 14.95 | AQST lower |
| Revenue growth (YoY) as of 2026-08-10 | -7.3% | +41.1% | HALO higher |
| Revenue CAGR (3y) SEC XBRL | -2.2% | +28.4% | HALO higher |
| Beta as of 2026-08-10 | 1.46 | 0.90 | |
| 1-year return as of 2026-08-07 close | +0.3% | +66.1% | HALO higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.